Skip to Content
May 18 2022
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for
May 11 2022
PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 11, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the " Company "), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that
Apr 11 2022
Data presented at the 2022 Annual Meeting of the American Association of Cancer Research New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT showed that groups that